AstraZeneca Recentin To Start Phase III For Colorectal Cancer, But Not NSCLC
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Phase II non-small cell lung cancer data on cediranib did not meet criteria for Phase III, and showed imbalance in toxicity